Retatrutide produced 28.7% body weight loss at 68 weeks in Phase 3 trials
The takeaway: most people will not experience this side effect, and for non-diabetic patients, the overall risk is considered extremely low
Samples were separated using a Kinetex 2.6 m XB-C18 100 , 100 2.1 mm LC Column (Phenomenex) with a constant flow rate of 250 l/min following a flow gradient starting at 70% Mobile Phase B (ACN + 0.5% Acetic acid, AA) then going up to 99% for 5 min before re-equilibration at 70% for 5 min
Contact a healthcare professional immediately if you experience: Difficulty breathing or shortness of breath
Estimativa 2014: Incidncia de Cncer no Brasil
Manfredi Rizzo is former Director, Clinical Medical & Regulatory Department, Novo Nordisk Europe East and South and has given lectures, received honoraria and research support, and participated in conferences, advisory boards and clinical trials sponsored by pharmaceutical industry including Amgen, AstraZeneca, Boehringer Ingelheim, Kowa, Eli Lilly, Meda, Mylan, Merck Sharp & Dohme, Novo Nordisk, Novartis, Roche Diagnostics, Sanofi and Servier
